Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Rating of “Moderate Buy” by Brokerages

Vir Biotechnology, Inc. (NASDAQ:VIR) has been assigned a consensus rating of “Moderate Buy” from the eleven analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $17.30.

A number of equities analysts have issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Monday, December 22nd. Evercore ISI initiated coverage on Vir Biotechnology in a research note on Wednesday, September 3rd. They issued an “outperform” rating and a $12.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Vir Biotechnology in a report on Monday, September 15th.

Vir Biotechnology Stock Performance

Vir Biotechnology stock opened at $6.00 on Monday. Vir Biotechnology has a fifty-two week low of $4.16 and a fifty-two week high of $14.45. The firm has a market capitalization of $834.72 million, a price-to-earnings ratio of -1.66 and a beta of 1.34. The stock’s fifty day moving average is $6.00 and its two-hundred day moving average is $5.50.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.47). The firm had revenue of $0.24 million for the quarter, compared to analyst estimates of $1.98 million. Vir Biotechnology had a negative return on equity of 50.76% and a negative net margin of 2,963.54%.The company’s quarterly revenue was up .8% compared to the same quarter last year. During the same period last year, the firm earned ($1.56) EPS. As a group, sell-side analysts forecast that Vir Biotechnology will post -3.92 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Jason O’byrne sold 6,799 shares of the business’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $5.56, for a total value of $37,802.44. Following the completion of the transaction, the chief financial officer owned 110,701 shares of the company’s stock, valued at approximately $615,497.56. The trade was a 5.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Vicki L. Sato sold 22,000 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $6.00, for a total transaction of $132,000.00. Following the sale, the director directly owned 1,188,391 shares in the company, valued at $7,130,346. This represents a 1.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 3,031,666 shares of company stock worth $18,292,045. 16.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. FNY Investment Advisers LLC acquired a new stake in shares of Vir Biotechnology during the third quarter worth $38,000. Hudson Bay Capital Management LP lifted its position in Vir Biotechnology by 31.0% during the third quarter. Hudson Bay Capital Management LP now owns 911,882 shares of the company’s stock worth $5,207,000 after buying an additional 215,882 shares during the period. Connective Capital Management LLC purchased a new position in Vir Biotechnology during the third quarter worth about $431,000. Sender Co & Partners Inc. acquired a new stake in Vir Biotechnology in the 3rd quarter worth about $247,000. Finally, Dark Forest Capital Management LP purchased a new stake in Vir Biotechnology in the 3rd quarter valued at about $817,000. 65.32% of the stock is currently owned by institutional investors and hedge funds.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.